Radiotherapy for prostate cancer adjusted during COVID-19

Radiotherapy for prostate cancer adjusted during COVID-19

(HealthDay)—In a special article published online April 1 in Advances in Radiation Oncology, a framework is laid out for the management of radiotherapy for prostate cancer patients during the coronavirus disease 2019 (COVID-19) pandemic.

Nicholas G. Zaorsky, M.D., from Penn State Cancer Institute in Hershey, and colleagues established recommendations and developed a Remote visits, and Avoidance, Deferment, and Shortening of radiotherapy (RADS) framework to evaluate and manage during the COVID-19 pandemic.

The researchers noted that telemedicine consultations and return visits are recommended when resources and staff are available across all stages. Based on the stage of , delays in consultation and return visits between one and six months were deemed safe. For very low, low, and favorable intermediate-risk disease, treatment can be avoided or delayed until safe. Neoadjuvant hormone therapy can be used for four to six months, as necessary, for unfavorable intermediate-risk, high-risk, clinical node-positive, recurrence postsurgery, oligometastatic, and low-volume M1 disease. For localized, oligometastatic, and low-volume M1 disease, ultrahypofractionation is preferred; for postprostatectomy and clinical node-positive disease, moderate hypofractionation is preferred. There is a preference for salvage to adjuvant radiation.

"These recommendations are not formal rules or policies, as we do not believe this is possible when data is so limited," the authors write. "Rather, the goal was to provide guidance and a framework of thinking of how numerous programs are approaching the care of patients with prostate at their own clinics, who are all at various stages of impact and restrictions from the COVID-19 global pandemic."

Explore further

Follow the latest news on the coronavirus (COVID-19) outbreak

More information: Abstract/Full Text

Copyright © 2020 HealthDay. All rights reserved.

Citation: Radiotherapy for prostate cancer adjusted during COVID-19 (2020, April 7) retrieved 25 May 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors